CYDY CytoDyn

CytoDyn to Hold Investment Community Conference Call on February 6, 2020

CytoDyn to Hold Investment Community Conference Call on February 6, 2020

VANCOUVER, Washington, Feb. 03, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., president and chief executive officer, and Bruce Patterson, M.D., chief executive officer and founder of IncellDx, a diagnostic partner and advisor to CytoDyn, will host an investment community conference call to provide a comprehensive update on Company developments. The conference call will focus on, amongst other updates, the following key agenda items:

  • Status of filing the Biologics License Application (BLA) for leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients
  • Update on CytoDyn’s therapeutic indications involving cancer
  • Update on potential use of leronlimab in China to treat the 2019 Novel Coronavirus (2019-nCov)

Date: Thursday, February 6, 2020

Time: 4:00 p.m. ET / 1:00 p.m. PT

Dial-In: 877-407-2986 US / 201-378-4916 International

A live audio webcast may also be accessed via CytoDyn’s corporate website at  under the Investors section/IR Calendar and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software. The webcast can also be accessed via the following link:

A replay of the conference call will be available until March 7, 2020. To access the replay, interested parties may dial 877-660-6853 (US) / 201-612-7415 (international) and enter conference identification number 13695017.

CONTACTS:

Media: 

Grace Fotiades

LifeSci Communications



(646) 876-5026



Investors:

Nader Pourhassan, Ph.D.

President & CEO

EN
03/02/2020

Underlying

CYDYCytoDyn

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CytoDyn

 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Co...

CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer Enrollment is now underway across multiple clinical sites, in partnership with Syneos Health VANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the first patient has been dosed in the Company’s clinical trial evaluating the efficacy of leronlimab in patients with relapsed/refractory microsatellite st...

June 24, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Releases ESMO Breast Cancer Meeting Poster

CytoDyn Releases ESMO Breast Cancer Meeting Poster VANCOUVER, Washington, May 15, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today shared the Company’s poster presented at the European Society for Medical Oncology’s (“ESMO”) Breast Cancer meeting on May 14-17, 2025, in Munich, Germany. A copy of the poster is available at the following link: More information about the data CytoDyn presented at ESMO suggesting the novel mechanis...

May 15, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronli...

CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors Survival observations in mTNBC patients correlated with increased PD-L1 expression Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot” VANCOUVER, Washington, May 13, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced new data suggesting a novel mechanism of action of leronlimab for th...

May 13, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial ...

CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Robert E. Hoffman has been appointed as Chief Financial Officer, effective May 15, 2025. He will take over the CFO position from Mitch Cohen, who had been serving as CFO on an interim basis since February 2024. Mr. Hoffman is an industry veteran with decades o...

May 6, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich...

CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany Dr. Jacob Lalezari, CEO, and Dr. Richard Pestell, Lead Consultant in Preclinical and Clinical Oncology, to lead CytoDyn group in attendance VANCOUVER, Washington, April 29, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, is pleased to announce that the Company will be presenting a poster at the upcoming European Society for Medical Oncology’s (“ESMO”) Brea...

April 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch